IJTI | INTERNATIONAL JOURNAL OF THERAPEUTIC INNOVATION

Review article

Drug resistance and current challenges to overcome

Mrunmayi Kakde

Santa Gadge Baba Amaravti University, Amaravti, Maharashtra, India

Corresponding author: Mrunmayi Kakde ✉ mskakde.bioinfo@gmail.com, **Orcid Id**: https://orcid.org/0009-0005-1991-0092

Received - 09-05-2023, **Revised** - 22-06-2023, **Accepted** - 27-07-2023 **(DD-MM-YYYY)**

Refer this article

Mrunmayi Kakde. Drug resistance and current challenges to overcome. International journal of therapeutic innovation, July-August 2023, V 1 - I 1, Pages - 0031 – 0037. Doi: https://doi.org/10.55522/ijti.V1I1.0011.

ABSTRACT

Drug resistance is a formidable obstacle in medicine, hindering the efficacy of treatments against pathogens and cancer cells. Grasping the mechanisms responsible for drug resistance is essential to devising effective solutions. This comprehensive review explores various resistance mechanisms, encompassing genetic mutations, drug efflux pumps, altered drug targets, and enhanced DNA repair mechanisms. Genetic mutations can modify drug target proteins or metabolic pathways, reducing drug effectiveness. Drug efflux pumps expel drugs from cells, lowering their concentration and effectiveness. Altered drug targets can result from mutations or modifications, diminishing drug binding or interactions. Enhanced DNA repair mechanisms further contribute to drug resistance by efficiently fixing drug-induced DNA damage. To combat drug resistance, a multifaceted approach is necessary. Strategies include combination therapies, innovative drugs targeting resistant pathways, and precision medicine. However, challenges persist, such as the emergence of new resistance mechanisms and limited comprehension of their interplay. A multidisciplinary approach, involving molecular biology, pharmacology, and computational modeling, is vital to surmount drug resistance and enhance patient outcomes. This review emphasizes the significance of ongoing efforts to tackle this global healthcare problem.

Keywords: Drug resistance, Drug efflux, Antibiotic stewardship programs, Bacterial biofilms, CRISPR, Vaccine development

INTRODUCTION

Drug resistance is a formidable challenge in modern medicine that compromises the effectiveness of therapeutic interventions against infectious diseases and cancer [1]. It refers to the ability of pathogens or cancer cells to withstand the effects of drugs that were once effective in eliminating or controlling them. The emergence and spread of drug-resistant strains have become a pressing global concern, leading to increased morbidity, mortality, and health care costs. Understanding the mechanisms underlying drug resistance and finding ways to overcome it are paramount for the development of effective treatment strategies [1, 2, and 3].

The importance of understanding drug resistance cannot be overstated. In the case of infectious diseases, such as bacterial infections and viral diseases like HIV and hepatitis, drug resistance can render previously potent antibiotics and antiviral agents ineffective, resulting in treatment failures [2]. This can lead to prolonged illnesses, increased transmission rates, and higher mortality rates. Similarly, in oncology, drug resistance poses a significant hurdle in the successful treatment of cancer patients. Cancer cells can acquire resistance to chemotherapy drugs, targeted therapies, and immunotherapies, leading to treatment resistance, disease progression, and reduced patient survival rates [1, 2, and 3].

Overcoming drug resistance is a complex and multifaceted challenge. Several factors contribute to the current difficulties faced in combating drug-resistant pathogens and cancer cells. One of the primary challenges is the limited development of new drugs. The pipeline for discovering and developing novel antimicrobial agents or cancer therapeutics has significantly dwindled in recent years, leaving healthcare providers with few new options to combat drug-resistant strains [3].

Another major challenge is the limited treatment options available for patients. In some cases, the development of resistance to multiple drugs, known as multidrug resistance, severely restricts the choices for effective treatment. This can lead to the use of older, less effective drugs with increased toxicity and reduced efficacy [1, 2, and 3].

Inadequate diagnostic methods also contribute to the challenge of drug resistance. Timely and accurate diagnosis of drug-resistant strains is essential for appropriate treatment selection and patient management. However, diagnostic tests for drug resistance are often expensive, time-consuming, or not widely accessible, resulting in delayed or inappropriate treatments [4].

Furthermore, the global spread of drug-resistant strains is a significant concern. The interconnectedness of the modern world facilitates the rapid dissemination of drug-resistant pathogens across countries and continents. International travel, medical tourism, and inadequate infection control measures contribute to the global transmission of resistant strains, making containment and control efforts more challenging [2, 4].

Moreover, the adaptive nature of pathogens and cancer cells presents an ongoing challenge. Microorganisms and cancer cells have the ability to evolve rapidly, adapting to drug pressures and developing new mechanisms of resistance. This evolutionary arms race necessitates continuous surveillance, research, and development of novel strategies to stay one step ahead of drug-resistant strains [1, 2, and 4].

Drug resistance poses a serious threat to public health, patient outcomes, and healthcare systems worldwide. Understanding the mechanisms of drug resistance and finding innovative solutions to overcome it are crucial. This review article will delve into the mechanisms of drug resistance, explore the major types of drug resistance, discuss the current challenges faced in combating drug resistance, and highlight potential strategies and technological advances to address this critical issue. By comprehensively addressing the challenges and potential solutions, we can pave the way for the development of effective interventions to combat drug resistance and safeguard the future of medicine.

Mechanisms of Drug Resistance

Drug resistance, the ability of pathogens or cancer cells to withstand the effects of therapeutic drugs, is a complex phenomenon driven by various mechanisms. Understanding these mechanisms is crucial for developing effective strategies to overcome drug resistance. Four major mechanisms include genetic mutations, drug efflux pumps, altered drug targets, and enhanced DNA repair mechanisms.

Genetic Mutations

Genetic mutations play a significant role in the development of drug resistance. Pathogens and cancer cells can acquire mutations in their genetic material, including genes involved in drug targets or metabolic pathways, leading to reduced drug efficacy. These mutations can result in alterations in protein structure or function, preventing drugs from effectively binding to their targets [5].

For example, in bacterial infections, genetic mutations can occur in genes encoding enzymes targeted by antibiotics. The mutations may alter the structure of these enzymes, rendering them less susceptible to drug inhibition. One well-known example is the development of resistance to the antibiotic rifampicin in Mycobacterium tuberculosis due to mutations in the rpoB gene, which encodes the RNA polymerase beta subunit [6]. Similarly, in cancer, genetic mutations can give rise to resistance to chemotherapy drugs. Mutations in genes involved in drug transport, DNA repair, or apoptotic pathways can confer resistance to cytotoxic agents. The emergence of mutations in the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients treated with EGFR inhibitors is a classic example of acquired resistance [5,7].

Drug Efflux Pumps

Dug efflux pumps are specialized membrane transport proteins that actively pump drugs out of cells, reducing their intracellular concentration and efficacy. These pumps play a crucial role in multidrug resistance, where pathogens or cancer cells become resistant to multiple drugs simultaneously [8].

In bacteria, efflux pumps can extrude a wide range of antibiotics, limiting their intracellular accumulation and preventing their action. One well-known family of efflux pumps is the ATP-binding cassette (ABC) transporters, which utilize ATP to actively export drugs across the bacterial membrane. The over expression of these pumps, such as the

AcrAB-TolC system in Escherichia coli, confers resistance to various antibiotics [9].

In cancer cells, efflux pumps belonging to the ATP-binding cassette super family, including P-glycoprotein (P-gp), can actively pump out chemotherapeutic drugs from cancer cells, reducing their cytotoxic effects. The over expression of P-gp has been associated with resistance to a broad spectrum of anticancer drugs, including anthracyclines and taxanes [9].

Altered Drug Targets

Another mechanism of drug resistance involves alterations in the drug target proteins themselves. Pathogens or cancer cells can undergo changes in drug target proteins, either through mutations or modifications, which diminish drug binding affinity or prevent drug-target interactions.In bacteria, resistance can arise from mutations in genes encoding drug targets, such as bacterial enzymes or ribosomal proteins. These mutations can result in confirmation changes that hinder drug binding or reduce drug-target affinity. For example, mutations in the gyrA gene encoding the DNA gyrase enzyme are associated with resistance to fluoroquinolone antibiotics in several bacterial species [10].

In cancer, alterations in drug targets can confer resistance to targeted therapies. These alterations may include mutations or amplification of the target genes, which lead to changes in protein structure or expression levels. For instance, resistance to the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) is frequently associated with the emergence of BCR-ABL kinase domain mutations that impair drug binding [11].

D. Enhanced DNA Repair Mechanisms

Enhanced DNA repair mechanisms contribute to drug resistance by enabling the rapid repair of drug-induced DNA damage, thereby reducing the efficacy of genotoxic drugs. When cells are exposed to DNA-damaging agents such as chemotherapy drugs or radiation, the DNA repair machinery is activated to fix the damage. However, in drug-resistant cells, these repair mechanisms are often altered, leading to more efficient repair and reduced drug-induced DNA damage [12].

One example of enhanced DNA repair mechanisms is the upregulation of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) in cancer cells. PARP plays a crucial role in base excision repair, a pathway involved in the repair of DNA single-strand breaks. Overexpression of PARP can enhance the repair capacity of cancer cells and confer resistance to PARP inhibitors, a class of targeted cancer therapies [13].

In addition to upregulated repair enzymes, alterations in DNA repair pathways themselves can contribute to drug resistance. For instance, defects in the DNA mismatch repair pathway have been associated with resistance to certain chemotherapeutic agents, such as the alkylating agent temozolomide in glioblastoma multiforme [14].

Understanding and targeting these enhanced DNA repair mechanisms hold promise for overcoming drug resistance. By inhibiting specific DNA repair enzymes or pathways, it may be possible to sensitize drug-resistant cells to genotoxic therapies and improve treatment outcomes [12, 13, and 14].

Major Types of Drug Resistance

Antibiotic resistance

Antibiotic resistance is a growing global concern that poses a significant threat to public health. It refers to the ability of bacteria to survive and multiply in the presence of antibiotics, rendering these drugs ineffective in treating infections. The emergence and spread of antibiotic resistance are primarily driven by several factors, including the misuse and overuse of antibiotics, inadequate infection prevention and control measures, and the natural ability of bacteria to adapt and evolve.

To gain a better understanding of antibiotic resistance and its implications, numerous studies have been conducted worldwide. One comprehensive review by Ventola provides a detailed analysis of the current state of antibiotic resistance, including its causes, mechanisms, and global impact. The review highlights the urgent need for effective strategies to combat antibiotic resistance, such as the development of new antibiotics, improved diagnostic techniques, and enhanced infection prevention practice [1]. Furthermore, a study by Davies and Davies explores the various mechanisms bacteria employ to resist antibiotics, including the modification of drug targets, drug efflux pumps, and the acquisition of resistance genes through horizontal gene transfer [15]. Understanding these mechanisms is crucial in the development of new therapeutic approaches to combat antibiotic resistance.

A. Antiviral drug resistance

Antiviral drug resistance is a significant concern in the field of virology, as it can limit the effectiveness of antiviral therapies and hinder the control of viral infections. Similar to antibiotic resistance, antiviral drug resistance occurs when viruses mutate and acquire genetic changes that allow them to evade the effects of antiviral drugs. This can lead to treatment failure, disease progression, and the potential for the spread of drug-resistant viral strains [16, 17].

Numerous studies have investigated antiviral drug resistance in various viral infections. For example, a study by Tang and Shafer provides an overview of the mechanisms underlying antiviral drug resistance in human immunodeficiency virus (HIV) infections. The review discusses the development of resistance mutations, the impact of drug resistance on treatment outcomes, and strategies to overcome resistance in HIV therapy [16].

Another study on drug resistance in hepatitis C virus (HCV) infections that discuss the genetic and phenotypic factors that contribute to HCV drug resistance, the role of viral quasispecies in resistance development, and the implications for the selection of antiviral treatment regimens is a good example of antiviral drug resistance [17].

Understanding the mechanisms of antiviral drug resistance is essential for the development of effective antiviral therapies and the implementation of appropriate treatment strategies. By monitoring and studying drug-resistant viral strains, researchers can identify new targets for antiviral drugs and design combination therapies that minimize the risk of resistance development.

Anticancer drug resistance

Cancer drug resistance is a significant challenge in cancer treatment that can limit the effectiveness of chemotherapy and targeted therapies. It refers to the ability of cancer cells to adapt and survive despite exposure to anticancer drugs.

Numerous studies have investigated the mechanisms and implications of anticancer drug resistance. A study by Behzad Mansoori focuses on multidrug resistance, a common form of resistance in cancer cells. The authors discuss the role of ATP-binding cassette (ABC) transporters in pumping out anticancer drugs from cancer cells, leading to reduced drug accumulation and treatment failure [18].

Understanding the mechanisms of anticancer drug resistance is crucial for developing strategies to overcome resistance and improve treatment outcomes. This includes the development of new drugs that can bypass resistance mechanisms, combination therapies, and personalized treatment approaches tailored to individual patients' genetic profiles.

Current Challenges in Overcoming Drug Resistance

Drug resistance has emerged as a significant challenge in healthcare, impacting the effectiveness of various treatment approaches and posing a threat to global public health. The ability of pathogens to adapt and develop resistance to antimicrobial agents is a complex phenomenon influenced by various factors, including genetic mutations, selective pressures, and the widespread use and misuse of drugs. This review aims to explore the current challenges associated with overcoming drug resistance, highlighting the lack of new drug development, limited treatment options, inadequate diagnostic methods, the global spread of resistant strains, and the evolutionary adaptation of pathogens. Understanding these challenges is crucial for the development of effective strategies to combat drug resistance and ensure the continued efficacy of antimicrobial therapies.

Lack of new drug development

One of the primary challenges in overcoming drug resistance is the lack of new drug development. The discovery and development of new drugs are complex and costly processes, often taking several years to bring a drug to market. Factors such as scientific challenges, high failure rates in clinical trials, regulatory hurdles, and financial considerations have contributed to the decline in the development of novel antibiotics and antivirals. The over-reliance on existing drug classes has led to the rapid emergence and spread of resistance. Addressing this challenge requires increased investment in research and development, novel drug discovery approaches, and collaborative efforts between academia, industry, and regulatory agencies [1, 15, and 19].

Limited treatment options

The emergence of drug-resistant strains has significantly limited the treatment options available for many infections and cancers. In some cases, there may be only a few remaining drugs effective against a particular resistant strain, leading to compromised treatment outcomes. The limited arsenal of effective drugs is particularly evident in the field of antibiotic resistance, where the development of new antibiotics has stagnated. To overcome this challenge, a multi-pronged approach is needed, including the repurposing of existing drugs, combination therapies, and the development of alternative treatment modalities such as phage therapy, immunotherapy, and nanoparticles-based drug delivery systems [1, 2, 15, and 19].

Inadequate diagnostic methods

Accurate and timely diagnosis is essential for effective treatment and prevention of the spread of drug resistance. However, current diagnostic methods may have limitations in detecting drug-resistant strains or providing rapid results. Traditional culture-based methods can be time-consuming, and their sensitivity may vary. Inadequate diagnostics can lead to delayed treatment decisions, inappropriate use of broad-spectrum antibiotics, and the potential for the selection and spread of resistant strains. Overcoming this challenge requires the development and implementation of advanced diagnostic technologies, such as molecular testing, next-generation sequencing, and point-of-care assays, which can provide rapid and accurate detection of drug-resistant pathogens [1, 15, and 19].

Global spread of resistant strains

Drug-resistant strains can spread rapidly across regions, countries, and continents, posing a global threat to public health. Factors contributing to the global spread of drug resistance include international travel, inadequate infection control practices, suboptimal antimicrobial stewardship, and the interconnectedness of our modern world. Addressing this challenge requires a collaborative approach involving enhanced surveillance systems, implementation of effective infection control measures, promotion of antimicrobial stewardship programs, and international cooperation to prevent the spread of drug-resistant strains [1, 15, and 19].

Evolutionary adaptation of pathogens

Pathogens possess an extraordinary ability to adapt and evolve in response to selective pressures exerted by drugs. This evolutionary adaptation can lead to the emergence of resistant strains with enhanced survival and proliferation capabilities. Pathogens can acquire resistance through various mechanisms, including genetic mutations, acquisition of resistance genes through horizontal gene transfer, and phenotypic changes. Understanding the molecular mechanisms of resistance and the evolutionary dynamics of pathogens is crucial for developing strategies to overcome resistance. This includes the use of advanced genomic sequencing, computational modeling, and systems biology approaches to identify new drug targets, understand the mechanisms of resistance, and optimize treatment regimens [1, 15, and 19].

Emerging Approaches and Future Directions

Antibiotic stewardship programs

Antibiotic stewardship programs aim to optimize the use of antibiotics by promoting appropriate prescribing practices, minimizing unnecessary use, and preventing the development of resistance. These programs involve a multidisciplinary approach, including education, guidelines, surveillance, and feedback to healthcare providers. By implementing antibiotic stewardship programs, healthcare facilities can reduce the emergence and spread of drug-resistant bacteria, preserve the effectiveness of available antibiotics, and enhance patient safety [20].

Targeting bacterial biofilms

Bacterial biofilms play a crucial role in the persistence of infections and the development of drug resistance. Biofilms provide a protective environment for bacteria, rendering them less susceptible to antibiotics and the immune system. Emerging approaches to target biofilms include the use of biofilm-disrupting agents, combination therapies, and antimicrobial peptides. Novel strategies such as nanotechnology-based approaches, quorum sensing inhibitors, and biofilm-specific targeting agents show promise in eradicating biofilms and preventing the emergence of drug-resistant strains [21, 22].

CRISPR-based antimicrobial strategies

The revolutionary CRISPR-Cas system has the potential to revolutionize antimicrobial research. CRISPR-based strategies can specifically target and cleave bacterial DNA, offering a precise and programmable method to disrupt or eliminate drug-resistant pathogens. CRISPR-based antimicrobial strategies include CRISPR-Cas antimicrobials, phage therapy combined with CRISPR-Cas systems, and CRISPR-based diagnostics for rapid detection of resistance genes. However, challenges such as delivery methods, off-target effects, and resistance to CRISPR systems need to be addressed for effective implementation.

Vaccine development

Vaccines are a promising approach to combat drug resistance by preventing infections in the first place. Vaccines stimulate the immune system to recognize and target specific pathogens, reducing the reliance on antibiotics. Advancements in vaccine technology, such as the use of novel adjuvants and bioinformatics-driven antigen design, have facilitated the development of effective vaccines against drug-resistant pathogens. Furthermore, the development of broadly protective vaccines targeting conserved antigens holds great potential for tackling multiple drug-resistant strains [23].

CONCLUSION

Drug resistance poses a significant challenge in medicine, affecting infectious diseases and cancer treatment. Understanding its mechanisms, including genetic mutations and altered targets, is vital for effective strategies. Researchers explore combination therapies, personalized medicine, and novel drugs. Overcoming resistance requires multidisciplinary efforts considering disease characteristics and new mechanisms. Targeting specific resistances and surveillance programs are crucial. Collaboration among scientists, healthcare providers, and policymakers is vital for improved patient outcomes and sustainable treatments.

REFERENCES

1. Ventola CL, 2015. The antibiotic resistance crisis: part 1: causes and threats. P&T: a peer-reviewed journal for formulary management. 40(4), Pages 277-283.

2. Joo HS, Fu CI, Otto M, 2016. Bacterial strategies of resistance to antimicrobial peptides. Philosophical Transactions of the Royal Society B. 371(1695), Pages 20150292. Doi:10.1098/rstb.2015.0292.

3. Knight GM, Glover RE, McQuaid CF, et al, 2021. Antimicrobial resistance and COVID-19: Intersections and implications. Elife. 10, Pages 64139. Doi: 10.7554/eLife.64139.

4. Ghosh A, Saran N, Saha S, 2020. Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. Sci Rep. 10(1), Pages 8957. Doi: 10.1038/s41598-020-65766-8.

5. Garcia L, Alonso-Sanz M, Rebollo MJ, et al, 2001. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis isolates in Spain and their rapid detection by PCR-enzyme-linked immunosorbent assay. Journal of Clinical Microbiology. 39(5), Pages1813-1818. Doi: 10.1128/JCM.39.5.1813-1818.2001.

6. Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K, 2021.Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences. 22(2), Page 593. Doi: 10.3390/ijms22020593.

7. Li XZ, Plésiat P, Nikaido H, 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Clinical Microbiology Reviews. 28(2), Pages 337-418. Doi: 10.1128/CMR.00117-14.

8. Choi CH, 2005. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.Cancer cell international. Pages 5-30. Doi: 10.1186/1475-2867-5-30.

9. Pourahmad Jaktaji R, Mohiti E, 2010. Study of Mutations in the DNA gyrase gyrA Gene of Escherichia coli. Iranian Journal of Pharmaceutical Research. 9(1), Pages 43-48.

10. Khorashad JS, Kelley TW, Szankasi P, et al, 2013. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121(3), Pages 489-498. Doi: 10.1182/blood-2012-05-431379.

11. Tiek D, Cheng SY, 2022. DNA damage and metabolic mechanisms of cancer drug resistance.Cancer Drug Resistance. 5(2), Pages 368-379. Doi: 10.20517/cdr.2021.148

12. Ossovskaya V, Koo IC, Kaldjian EP, et al, 2010. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer. 1(8), Pages 812-821. Doi: 10.1177/1947601910383418.

13. Strobel H, Baisch T, Fitzel R, et al, 2019. Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines. 7(3), Pages 69. Doi: 10.3390/biomedicines7030069.

14. Davies J, Davies D, 2010. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews. 74(3), Pages 417-433. Doi: 10.1128/MMBR.00016-10.

15. Tang MW, Shafer RW, 2012. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 72(9), Pages 25. Doi: 10.2165/11633630-000000000-00000.

16. Salvatierra K, Fareleski S, Forcada A et al, 2013. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.World Journal of Virology. 2(1), Pages 6-15. Doi:10.5501/wjv.v2.i1.6.

17. Mansoori B, Mohammadi A, Davudian S, et al, 2017. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 7(3), Pages 339-348. Doi: 10.15171/apb.2017.041.

18. Spellberg B, Guidos R, Gilbert D, et al, 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious DiseasesSociety of America.Clinical Infectious Diseases, 46(2), Pages 55-164. Doi: 10.1086/524891.

19. Septimus EJ, 2018. Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach.Medical Clinics of North America, 102(5), Pages 819-829. Doi: 10.1016/j.mcna.2018.04.005.

20. Jiang Y, Geng M, Bai L. 2020. Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles. Microorganisms. 8(8), Pages 1222. Doi: 10.3390/microorganisms8081222.

21. Flemming HC, Wingender J, Szewzyk U,et al, 2016. Biofilms: an emergent form of bacterial life. Nature Reviews Microbiology, 14(9), Pages 563-575. Doi: 10.1038/nrmicro.2016.94.

22. Gomaa AA, Klumpe HE, Luo ML, et al, 2014. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio, 5(1), Pages 00928-13. Doi: 10.1128/mBio.00928-13.

23. Costanzo V, Roviello GN, 2023. The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR):

An Update and Future Perspectives.Vaccines (Basel). 11(2), Page 333. Doi: 10.3390/vaccines1102.